J Cancer 2020; 11(6):1315-1324. doi:10.7150/jca.39044 This issue


MicroRNA-183 in Cancer Progression

Dingren Cao1, Min Di2, Jingjie Liang1, Shuang Shi1, Qiang Tan1, Zhengguang Wang1✉

1. College of Animal Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.
2. Sir Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou, 310058, P. R. China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Cao D, Di M, Liang J, Shi S, Tan Q, Wang Z. MicroRNA-183 in Cancer Progression. J Cancer 2020; 11(6):1315-1324. doi:10.7150/jca.39044. Available from https://www.jcancer.org/v11p1315.htm

File import instruction


MicroRNA-183(miR-183) is abnormally expressed in many kinds of tumors. It participates in the initiation and development of tumors. There are many pathways regulate the expression of miR-183. The action mechanism of miR-183 in cancer is very extensive, and contradictory conclusions are often drawn. It was upregulated in 18 kinds of cancer, downregulated in 6 kinds of cancer. In addition, there are seven types of cancer, both upregulated and downregulated reports can be found. Evidence showed that miR-183 can not only directly play the role of oncogene or antioncogene, but also regulate the expression of other oncogene or antioncogene in different cancer types. In this review, we discuss the regulator of miR-183 and summarized the expression of miR-183 in different cancers. We also counted the target genes of miR-183 and the functional roles they play. Furthermore, we focused on the roles of miR-183 in cell migration, cell invasion, epithelial-mesenchymal transition (EMT) and microangiogenesis, which play the most important roles in cancer processes. It sheds light on the likely reasons why miR-183 plays different roles in various cancers. In addition, miR-183 and its downstream effectors have the potential to be promising prognostic markers and therapeutic targets in cancer.

Keywords: microRNA-183, cancer progression, EMT, metastasis, microangiogenesis